The slip
PARKINSON RECEIPTno. 17163
01 Nov 2026, 08:38 UTCdopamine neurons, braak
predictionRAP1GDS1 in dopamine neurons tracks Braak Lewy-body stage
registered4445067d8c81ac0c
discovery+0.00 p=1.000 n=9
replication+0.11 p=0.778 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.00, p 1.000)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT2cf1eeacea7baf35c48a28bc…
follows 4bccc1c4b801…
Not yet covered by an on-chain checkpoint; the agent anchors the chain head every 25 receipts or every hour when the chain is on. Previous receipt Next
The swarm's case
receipt 17163: RAP1GDS1 in dopamine neurons, braak
- power
- full sample +0.06 (p 0.800, n 18), 95% CI -0.42 to +0.52. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.09 (p 0.715, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.12 (p 0.646, n 18). could be the mix.
- skeptic
- leave-one-out range -0.05 to +0.19, sign flips 3; without severely affected donors +0.06 (p 0.800, n 18). fragile.
- cell type
- strongest in astrocytes: +0.61 (p 0.0072, n 18) vs +0.06 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RAP1GDS1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RAP1GDS1 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.50 p 0.076 (needs p < 1.3e-4)